In a groundbreaking preclinical study, NurExone Biologic Inc.’s ExoPTEN treatment enabled 100% of animals in the high-dose group to regain motor function after spinal cord injury. The dose-dependent study offers renewed hope for future therapies, with significant improvements confirmed using advanced gait analysis technology.